FDA Lifts Clinical Hold on Solid Biosciences’ DMD Gene Therapy Trial

FDA Lifts Clinical Hold on Solid Biosciences’ DMD Gene Therapy Trial

Source: 
BioSpace
snippet: 

Shares of Solid Biosciences skyrocketed more than 70% in premarket trading after the company announced the U.S. Food and Drug Administration (FDA) lifted the clinical hold on the company’s IGNITE DMD Phase I/II clinical trial.